Adjunctive therapy with perampanel reduces seizures in patients with drug-resistant primary generalized tonic–clonic seizures, a recent trial shows. 162 patients on antiepileptic drugs were randomly allocated to also receive either perampanel or a placebo during a 4-week titration period, followed by a 13-week maintenance period. Seizure frequency per 28 days was reduced by 76.5% in patients who received perampanel, but only by 38.4% in patients who received the placebo. 30.9% of patients who received parempanel and 12.3% of patients who received the placebo became free of seizures during maintenance.